ASTRAZENECA is cutting nearly a quarter of its US sales force in a second wave of redundancies in as many months as it seeks to reduce costs.
Britain's second biggest drugmaker said yesterday it would cut about 1,150 sales representative and management jobs at a cost of between $50m (€37m) and $100m (€74m), charged in the fourth quarter.
Rich Fante, president of AstraZeneca US, said it was a difficult decision to make the reductions, which represented 24pc of the US sales organisation and came on top of 400 US job losses announced in October.
"The changes we are making, however, will help us deliver better results for our business and, most importantly, continue delivering on our mission of patient health," he said. (Reuters)